{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T08:14:51Z","timestamp":1780647291648,"version":"3.54.1"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T00:00:00Z","timestamp":1732752000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T00:00:00Z","timestamp":1732752000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"crossref","award":["No. 2023M741506"],"award-info":[{"award-number":["No. 2023M741506"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100007129","name":"Shandong Provincial Natural Science Foundation","doi-asserted-by":"crossref","award":["No. ZR2023QH193"],"award-info":[{"award-number":["No. ZR2023QH193"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation","doi-asserted-by":"crossref","award":["No.82270200, No.82070203 and No.81770210"],"award-info":[{"award-number":["No.82270200, No.82070203 and No.81770210"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Taishan Scholars Program of Shandong Province","award":["None"],"award-info":[{"award-number":["None"]}]},{"name":"Shandong Provincial Engineering Research Center of Lymphoma","award":["None"],"award-info":[{"award-number":["None"]}]},{"DOI":"10.13039\/100014103","name":"Key Research and Development Program of Shandong Province","doi-asserted-by":"crossref","award":["No.2018CXGC1213"],"award-info":[{"award-number":["No.2018CXGC1213"]}],"id":[{"id":"10.13039\/100014103","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Academic Promotion Programme of Shandong First Medical University","award":["No. 2019QL018"],"award-info":[{"award-number":["No. 2019QL018"]}]},{"name":"Translational Research Grant of NCRCH","award":["No.2021WWB02, No.2020ZKMB01"],"award-info":[{"award-number":["No.2021WWB02, No.2020ZKMB01"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s00277-024-06109-9","type":"journal-article","created":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T02:50:39Z","timestamp":1732762239000},"page":"5557-5572","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Novel serous effusion-related risk models and biomarkers for predicting prognosis in T-cell lymphoma patients"],"prefix":"10.1007","volume":"103","author":[{"given":"Juanjuan","family":"Shang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoli","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingyu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunfeng","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,28]]},"reference":[{"issue":"7","key":"6109_CR1","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","volume":"36","author":"R Alaggio","year":"2022","unstructured":"Alaggio R, Amador C, Anagnostopoulos I et al (2022) The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: lymphoid neoplasms. Leukemia 36(7):1720\u20131748. https:\/\/doi.org\/10.1038\/s41375-022-01620-2","journal-title":"Leukemia"},{"issue":"9","key":"6109_CR2","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1182\/blood-2016-08-692566","volume":"129","author":"A Broccoli","year":"2017","unstructured":"Broccoli A, Zinzani PL (2017) Peripheral T-cell lymphoma, not otherwise specified. Blood 129(9):1103\u20131112. https:\/\/doi.org\/10.1182\/blood-2016-08-692566","journal-title":"Blood"},{"issue":"1","key":"6109_CR3","doi-asserted-by":"publisher","first-page":"e1491","DOI":"10.1002\/ctm2.1491","volume":"14","author":"C Wei","year":"2024","unstructured":"Wei C, Wang W, Li W et al (2024) Mutations of epigenetic genes and correlation with treatment response in peripheral T-cell lymphoma. Clin Transl Med 14(1):e1491. https:\/\/doi.org\/10.1002\/ctm2.1491","journal-title":"Clin Transl Med"},{"issue":"3","key":"6109_CR4","doi-asserted-by":"publisher","first-page":"285","DOI":"10.6004\/jnccn.2022.0015","volume":"20","author":"SM Horwitz","year":"2022","unstructured":"Horwitz SM, Ansell S, Ai WZ et al (2022) T-Cell Lymphomas, Version 2.2022, NCCN Clinical Practice guidelines in Oncology. J Natl Compr Canc Netw 20(3):285\u2013308. https:\/\/doi.org\/10.6004\/jnccn.2022.0015","journal-title":"J Natl Compr Canc Netw"},{"issue":"3","key":"6109_CR5","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1002\/ajh.27165","volume":"99","author":"SY Ong","year":"2024","unstructured":"Ong SY, Zain JM (2024) Aggressive T-cell lymphomas: 2024: updates on diagnosis, risk stratification, and management. Am J Hematol 99(3):439\u2013456. https:\/\/doi.org\/10.1002\/ajh.27165","journal-title":"Am J Hematol"},{"issue":"23","key":"6109_CR6","doi-asserted-by":"publisher","first-page":"5915","DOI":"10.1158\/1078-0432.CCR-15-1739","volume":"22","author":"K Nakano","year":"2016","unstructured":"Nakano K, Uchimaru K, Utsunomiya A, Yamaguchi K, Watanabe T (2016) Dysregulation of c-Myb pathway by aberrant expression of proto-oncogene MYB provides the basis for malignancy in adult t-cell leukemia\/lymphoma cells. Clin Cancer Res 22(23):5915\u20135928. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-1739","journal-title":"Clin Cancer Res"},{"issue":"2","key":"6109_CR7","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s00277-018-3515-2","volume":"98","author":"S Hu","year":"2019","unstructured":"Hu S, Zhou D, Wu Y et al (2019) Autoimmune disease-associated non-hodgkin\u2019s lymphoma-a large retrospective study from China. Ann Hematol 98(2):445\u2013455. https:\/\/doi.org\/10.1007\/s00277-018-3515-2","journal-title":"Ann Hematol"},{"issue":"1","key":"6109_CR8","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1111\/bjh.17638","volume":"196","author":"NK El-Mallawany","year":"2022","unstructured":"El-Mallawany NK, Curry CV, Allen CE (2022) Haemophagocytic lymphohistiocytosis and Epstein-Barr virus: a complex relationship with diverse origins, expression and outcomes. Br J Haematol 196(1):31\u201344. https:\/\/doi.org\/10.1111\/bjh.17638","journal-title":"Br J Haematol"},{"issue":"16","key":"6109_CR9","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1200\/JCO.2012.44.7524","volume":"31","author":"V Mak","year":"2013","unstructured":"Mak V, Hamm J, Chhanabhai M et al (2013) Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors. J Clin Oncol 31(16):1970\u20131976. https:\/\/doi.org\/10.1200\/JCO.2012.44.7524","journal-title":"J Clin Oncol"},{"issue":"8","key":"6109_CR10","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.3324\/haematol.2022.281510","volume":"108","author":"T Kameda","year":"2023","unstructured":"Kameda T, Kataoka K, Kamiunten A et al (2023) Integrated genetic and clinical prognostic factors for aggressive adult T-cell leukemia\/lymphoma. Haematologica 108(8):2178\u20132191. https:\/\/doi.org\/10.3324\/haematol.2022.281510","journal-title":"Haematologica"},{"issue":"12","key":"6109_CR11","doi-asserted-by":"publisher","first-page":"3402","DOI":"10.1182\/blood-2010-09-310342","volume":"117","author":"DD Weisenburger","year":"2011","unstructured":"Weisenburger DD, Savage KJ, Harris NL et al (2011) Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project. Blood 117(12):3402\u20133408. https:\/\/doi.org\/10.1182\/blood-2010-09-310342","journal-title":"Blood"},{"key":"6109_CR12","doi-asserted-by":"publisher","unstructured":"(1993) A predictive model for aggressive non-Hodgkin\u2019s lymphoma. N Engl J Med 329(14):987\u2013994. https:\/\/doi.org\/10.1056\/NEJM199309303291402","DOI":"10.1056\/NEJM199309303291402"},{"issue":"7","key":"6109_CR13","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1182\/blood-2003-09-3080","volume":"103","author":"A Gallamini","year":"2004","unstructured":"Gallamini A, Stelitano C, Calvi R et al (2004) Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood 103(7):2474\u20132479. https:\/\/doi.org\/10.1182\/blood-2003-09-3080","journal-title":"Blood"},{"issue":"5","key":"6109_CR14","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1002\/cncy.21257","volume":"121","author":"LC Tong","year":"2013","unstructured":"Tong LC, Ko HM, Saieg MA, Boerner S, Geddie WR, Da CSG (2013) Subclassification of lymphoproliferative disorders in serous effusions: a 10-year experience. Cancer Cytopathol 121(5):261\u2013270. https:\/\/doi.org\/10.1002\/cncy.21257","journal-title":"Cancer Cytopathol"},{"issue":"4","key":"6109_CR15","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1002\/cam4.2809","volume":"9","author":"Z Chen","year":"2020","unstructured":"Chen Z, Wang Y, Fang M (2020) Analysis of tumor markers in pleural effusion and serum to verify the correlations between serum tumor markers and tumor size, TNM stage of lung adenocarcinoma. Cancer Med 9(4):1392\u20131399. https:\/\/doi.org\/10.1002\/cam4.2809","journal-title":"Cancer Med"},{"issue":"4","key":"6109_CR16","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1093\/ajcp\/aqac170","volume":"159","author":"J Li","year":"2023","unstructured":"Li J, Zhu X, Deng X et al (2023) Angioimmunoblastic T-Cell lymphoma diagnosed from serous effusion by integration of cytologic features and ancillary studies. Am J Clin Pathol 159(4):379\u2013394. https:\/\/doi.org\/10.1093\/ajcp\/aqac170","journal-title":"Am J Clin Pathol"},{"key":"6109_CR17","doi-asserted-by":"publisher","unstructured":"Roberts ME, Neville E, Berrisford RG, Antunes G, Ali NJ (2010) Management of a malignant pleural effusion: British thoracic Society Pleural Disease Guideline 2010. Thorax 65 Suppl 2i32\u201340. https:\/\/doi.org\/10.1136\/thx.2010.136994","DOI":"10.1136\/thx.2010.136994"},{"issue":"21","key":"6109_CR18","doi-asserted-by":"publisher","first-page":"377","DOI":"10.3238\/arztebl.2019.0377","volume":"116","author":"B Jany","year":"2019","unstructured":"Jany B, Welte T (2019) Pleural effusion in Adults-Etiology, diagnosis, and treatment. Dtsch Arztebl Int 116(21):377\u2013386. https:\/\/doi.org\/10.3238\/arztebl.2019.0377","journal-title":"Dtsch Arztebl Int"},{"issue":"4","key":"6109_CR19","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1097\/JTO.0b013e318208ec77","volume":"6","author":"S Niho","year":"2011","unstructured":"Niho S, Kubota K, Yoh K et al (2011) Clinical outcome of small cell lung cancer with pericardial effusion but without distant metastasis. J Thorac Oncol 6(4):796\u2013800. https:\/\/doi.org\/10.1097\/JTO.0b013e318208ec77","journal-title":"J Thorac Oncol"},{"key":"6109_CR20","doi-asserted-by":"publisher","first-page":"850290","DOI":"10.3389\/fgene.2022.850290","volume":"13","author":"J He","year":"2022","unstructured":"He J, Hu X, Chen L, Liu Q, Jiang Y (2022) Characteristics of genomic alterations in pericardial effusion of advanced non-small cell lung cancer. Front Genet 13:850290. https:\/\/doi.org\/10.3389\/fgene.2022.850290","journal-title":"Front Genet"},{"issue":"3","key":"6109_CR21","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1038\/s41418-021-00880-2","volume":"29","author":"S Hu","year":"2022","unstructured":"Hu S, Ren S, Cai Y et al (2022) Glycoprotein PTGDS promotes tumorigenesis of diffuse large B-cell lymphoma by MYH9-mediated regulation of wnt-beta-catenin-STAT3 signaling. Cell Death Differ 29(3):642\u2013656. https:\/\/doi.org\/10.1038\/s41418-021-00880-2","journal-title":"Cell Death Differ"},{"issue":"2","key":"6109_CR22","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.cell.2018.02.052","volume":"173","author":"J Liu","year":"2018","unstructured":"Liu J, Lichtenberg T, Hoadley KA et al (2018) An integrated TCGA Pan-cancer clinical data resource to drive high-quality survival outcome analytics. Cell 173(2):400\u2013416. https:\/\/doi.org\/10.1016\/j.cell.2018.02.052","journal-title":"Cell"},{"key":"6109_CR23","doi-asserted-by":"publisher","unstructured":"Maeser D, Gruener RF, Huang RS (2021) OncoPredict: an R package for predicting in vivo or cancer patient drug response and biomarkers from cell line screening data. Brief Bioinform 2(6). https:\/\/doi.org\/10.1093\/bib\/bbab260","DOI":"10.1093\/bib\/bbab260"},{"key":"6109_CR24","doi-asserted-by":"publisher","unstructured":"(2024) Expert consensus on diagnosis and treatment of malignant pleural effusion caused by lung cancer. Zhonghua Zhong Liu Za Zhi 23;46(1):40\u201347. https:\/\/doi.org\/10.3760\/cma.j.cn112152-20231130-00344","DOI":"10.3760\/cma.j.cn112152-20231130-00344"},{"issue":"9","key":"6109_CR25","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1093\/carcin\/bgu130","volume":"35","author":"C Olga Vaksman","year":"2014","unstructured":"Olga Vaksman C, Trop\u00e9 B, Davidson R Reich (2014) Exosome-derived miRNAs and ovarian carcinoma progression. Carcinogenesis 35(9):2113\u20132120. https:\/\/doi.org\/10.1093\/carcin\/bgu130","journal-title":"Carcinogenesis"},{"issue":"5","key":"6109_CR26","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1002\/cam4.1000","volume":"6","author":"Q Qian","year":"2017","unstructured":"Qian Q, Sun W, Wen, Zhu et al (2017) The role of microRNA-93 regulating angiopoietin2 in the formation of malignant pleural effusion. Cancer Med 6(5):1036\u20131048. https:\/\/doi.org\/10.1002\/cam4.1000","journal-title":"Cancer Med"},{"key":"6109_CR27","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s12890-015-0025-z","volume":"15","author":"MM Zamboni","year":"2015","unstructured":"Zamboni MM, Da SCJ, Baretta R, Cunha ET, Cardoso GP (2015) Important prognostic factors for survival in patients with malignant pleural effusion. Bmc Pulm Med 15:29. https:\/\/doi.org\/10.1186\/s12890-015-0025-z","journal-title":"Bmc Pulm Med"},{"issue":"2","key":"6109_CR28","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1038\/s41565-021-01032-w","volume":"17","author":"Y Liu","year":"2022","unstructured":"Liu Y, Wang L, Song Q et al (2022) Intrapleural nano-immunotherapy promotes innate and adaptive immune responses to enhance anti-PD-L1 therapy for malignant pleural effusion. Nat Nanotechnol 17(2):206\u2013216. https:\/\/doi.org\/10.1038\/s41565-021-01032-w","journal-title":"Nat Nanotechnol"},{"key":"6109_CR29","doi-asserted-by":"publisher","unstructured":"Mulet M, Osuna-Gomez R, Zamora C et al (2022) Influence of malignant pleural fluid from lung adenocarcinoma patients on Neutrophil Response. Cancers (Basel) 14(10). https:\/\/doi.org\/10.3390\/cancers14102529","DOI":"10.3390\/cancers14102529"},{"issue":"1","key":"6109_CR30","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1186\/s12885-017-3550-8","volume":"17","author":"YS Lee","year":"2017","unstructured":"Lee YS, Nam HS, Lim JH et al (2017) Prognostic impact of a new score using neutrophil-to-lymphocyte ratios in the serum and malignant pleural effusion in lung cancer patients. BMC Cancer 17(1):557. https:\/\/doi.org\/10.1186\/s12885-017-3550-8","journal-title":"BMC Cancer"},{"issue":"1","key":"6109_CR31","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s12964-023-01370-3","volume":"22","author":"M Ahmadi","year":"2024","unstructured":"Ahmadi M, Abbasi R, Rezaie J (2024) Tumor immune escape: extracellular vesicles roles and therapeutics application. Cell Commun Signal 22(1):9. https:\/\/doi.org\/10.1186\/s12964-023-01370-3","journal-title":"Cell Commun Signal"},{"issue":"4","key":"6109_CR32","doi-asserted-by":"publisher","first-page":"167098","DOI":"10.1016\/j.bbadis.2024.167098","volume":"1870","author":"X Guo","year":"2024","unstructured":"Guo X, Bian X, Li Y, Zhu X, Zhou X (2024) The intricate dance of tumor evolution: exploring immune escape, tumor migration, drug resistance, and treatment strategies. Biochim Biophys Acta Mol Basis Dis 1870(4):167098. https:\/\/doi.org\/10.1016\/j.bbadis.2024.167098","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"issue":"1","key":"6109_CR33","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s12935-024-03211-w","volume":"24","author":"S Ge","year":"2024","unstructured":"Ge S, Zhao Y, Liang J et al (2024) Immune modulation in malignant pleural effusion: from microenvironment to therapeutic implications. Cancer Cell Int 24(1):105. https:\/\/doi.org\/10.1186\/s12935-024-03211-w","journal-title":"Cancer Cell Int"},{"issue":"4","key":"6109_CR34","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1002\/eji.201847685","volume":"49","author":"XZ Wu","year":"2019","unstructured":"Wu XZ, Zhai K, Yi FS et al (2019) IL-10 promotes malignant pleural effusion in mice by regulating T(H) 1- and T(H) 17-cell differentiation and migration. Eur J Immunol 49(4):653\u2013665. https:\/\/doi.org\/10.1002\/eji.201847685","journal-title":"Eur J Immunol"},{"issue":"3","key":"6109_CR35","doi-asserted-by":"publisher","first-page":"L443","DOI":"10.1152\/ajplung.00120.2018","volume":"315","author":"XZ Wu","year":"2018","unstructured":"Wu XZ, Shi XY, Zhai K et al (2018) Activated naive B cells promote development of malignant pleural effusion by differential regulation of T(H)1 and T(H)17 response. Am J Physiol Lung Cell Mol Physiol 315(3):L443\u2013L455. https:\/\/doi.org\/10.1152\/ajplung.00120.2018","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"issue":"1","key":"6109_CR36","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1186\/s12885-017-3615-8","volume":"17","author":"C Chen","year":"2017","unstructured":"Chen C, Qu QX, Xie F, Zhu WD, Zhu YH, Huang JA (2017) Analysis of B7-H4 expression in metastatic pleural adenocarcinoma and therapeutic potential of its antagonists. BMC Cancer 17(1):652. https:\/\/doi.org\/10.1186\/s12885-017-3615-8","journal-title":"BMC Cancer"},{"key":"6109_CR37","doi-asserted-by":"publisher","first-page":"1284853","DOI":"10.3389\/fimmu.2023.1284853","volume":"14","author":"C Li","year":"2023","unstructured":"Li C, Liu FY, Shen Y, Tian Y, Han FJ (2023) Research progress on the mechanism of glycolysis in ovarian cancer. Front Immunol 14:1284853. https:\/\/doi.org\/10.3389\/fimmu.2023.1284853","journal-title":"Front Immunol"},{"key":"6109_CR38","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.ejca.2016.03.012","volume":"60","author":"YL Chang","year":"2016","unstructured":"Chang YL, Yang CY, Lin MW, Wu CT, Yang PC (2016) High co-expression of PD-L1 and HIF-1alpha correlates with tumour necrosis in pulmonary pleomorphic carcinoma. Eur J Cancer 60:125\u2013135. https:\/\/doi.org\/10.1016\/j.ejca.2016.03.012","journal-title":"Eur J Cancer"},{"key":"6109_CR39","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.canlet.2018.11.023","volume":"442","author":"R Radhakrishnan","year":"2019","unstructured":"Radhakrishnan R, Ha JH, Jayaraman M et al (2019) Ovarian cancer cell-derived lysophosphatidic acid induces glycolytic shift and cancer-associated fibroblast-phenotype in normal and peritumoral fibroblasts. Cancer Lett 442:464\u2013474. https:\/\/doi.org\/10.1016\/j.canlet.2018.11.023","journal-title":"Cancer Lett"},{"issue":"1","key":"6109_CR40","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s13045-022-01292-6","volume":"15","author":"Q Wu","year":"2022","unstructured":"Wu Q, You L, Nepovimova E et al (2022) Hypoxia-inducible factors: Master regulators of hypoxic tumor immune escape. J Hematol Oncol 15(1):77. https:\/\/doi.org\/10.1186\/s13045-022-01292-6","journal-title":"J Hematol Oncol"},{"issue":"1","key":"6109_CR41","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s13046-015-0135-8","volume":"34","author":"T Hu","year":"2015","unstructured":"Hu T, He N, Yang Y, Yin C, Sang N, Yang Q (2015) DEC2 expression is positively correlated with HIF-1 activation and the invasiveness of human osteosarcomas. J Exp Clin Cancer Res 34(1):22. https:\/\/doi.org\/10.1186\/s13046-015-0135-8","journal-title":"J Exp Clin Cancer Res"},{"issue":"11","key":"6109_CR42","doi-asserted-by":"publisher","first-page":"9262","DOI":"10.3390\/cimb45110580","volume":"45","author":"K Kimura","year":"2023","unstructured":"Kimura K, Jackson T, Huang R (2023) Interaction and collaboration of SP1, HIF-1, and MYC in regulating the expression of Cancer-related genes to further enhance anticancer drug development. Curr Issues Mol Biol 45(11):9262\u20139283. https:\/\/doi.org\/10.3390\/cimb45110580","journal-title":"Curr Issues Mol Biol"},{"issue":"9","key":"6109_CR43","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1038\/sj.emboj.7600196","volume":"23","author":"M Koshiji","year":"2004","unstructured":"Koshiji M, Kageyama Y, Pete EA, Horikawa I, Barrett JC, Huang LE (2004) HIF-1alpha induces cell cycle arrest by functionally counteracting Myc. Embo J 23(9):1949\u20131956. https:\/\/doi.org\/10.1038\/sj.emboj.7600196","journal-title":"Embo J"},{"issue":"5","key":"6109_CR44","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1053\/j.gastro.2020.07.046","volume":"159","author":"A Tiwari","year":"2020","unstructured":"Tiwari A, Tashiro K, Dixit A et al (2020) Loss of HIF1A from pancreatic cancer cells increases expression of PPP1R1B and degradation of p53 to promote invasion and metastasis. Gastroenterology 159(5):1882\u20131897. https:\/\/doi.org\/10.1053\/j.gastro.2020.07.046","journal-title":"Gastroenterology"},{"issue":"3","key":"6109_CR45","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1158\/2159-8290.CD-15-0822","volume":"6","author":"KE Lee","year":"2016","unstructured":"Lee KE, Spata M, Bayne LJ et al (2016) Hif1a deletion reveals pro-neoplastic function of b cells in pancreatic neoplasia. Cancer Discov 6(3):256\u2013269. https:\/\/doi.org\/10.1158\/2159-8290.CD-15-0822","journal-title":"Cancer Discov"},{"issue":"3","key":"6109_CR46","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1158\/2159-8290.CD-11-0098","volume":"1","author":"C Shen","year":"2011","unstructured":"Shen C, Beroukhim R, Schumacher SE et al (2011) Genetic and functional studies implicate HIF1alpha as a 14q kidney cancer suppressor gene. Cancer Discov 1(3):222\u2013235. https:\/\/doi.org\/10.1158\/2159-8290.CD-11-0098","journal-title":"Cancer Discov"},{"issue":"1","key":"6109_CR47","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s12943-023-01904-w","volume":"23","author":"Y Luan","year":"2024","unstructured":"Luan Y, Li X, Luan Y et al (2024) Therapeutic challenges in peripheral T-cell lymphoma. Mol Cancer 23(1):2. https:\/\/doi.org\/10.1186\/s12943-023-01904-w","journal-title":"Mol Cancer"},{"key":"6109_CR48","doi-asserted-by":"publisher","unstructured":"Chen Y, Tao H, Wang F et al (2023) Artesunate synergistically promotes sorafenib\u2013induced apoptosis and ferroptosis in non\u2013Hodgkin lymphoma cells through inhibition of the STAT3 pathway. Oncol Rep 50(1). https:\/\/doi.org\/10.3892\/or.2023.8584","DOI":"10.3892\/or.2023.8584"},{"key":"6109_CR49","doi-asserted-by":"publisher","first-page":"101071","DOI":"10.1016\/j.blre.2023.101071","volume":"60","author":"SC Macapagal","year":"2023","unstructured":"Macapagal SC, Bennani NN (2023) Nodal peripheral T-cell lymphoma: chemotherapy-free management, are we there yet? Blood Rev 60:101071. https:\/\/doi.org\/10.1016\/j.blre.2023.101071","journal-title":"Blood Rev"},{"issue":"3","key":"6109_CR50","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1182\/bloodadvances.2020003429","volume":"5","author":"BS Moses","year":"2021","unstructured":"Moses BS, Mccullough S, Fox JM et al (2021) Antileukemic efficacy of a potent artemisinin combined with sorafenib and venetoclax. Blood Adv 5(3):711\u2013724. https:\/\/doi.org\/10.1182\/bloodadvances.2020003429","journal-title":"Blood Adv"},{"key":"6109_CR51","doi-asserted-by":"publisher","unstructured":"Gibson A, Trabal A, Mccall D et al (2021) Venetoclax for children and adolescents with acute lymphoblastic leukemia and lymphoblastic lymphoma. Cancers (Basel) 14(1). https:\/\/doi.org\/10.3390\/cancers14010150","DOI":"10.3390\/cancers14010150"},{"issue":"6","key":"6109_CR52","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1158\/2159-8290.CD-20-1465","volume":"11","author":"VA Pullarkat","year":"2021","unstructured":"Pullarkat VA, Lacayo NJ, Jabbour E et al (2021) Venetoclax and Navitoclax in combination with chemotherapy in patients with relapsed or refractory acute lymphoblastic leukemia and lymphoblastic lymphoma. Cancer Discov 11(6):1440\u20131453. https:\/\/doi.org\/10.1158\/2159-8290.CD-20-1465","journal-title":"Cancer Discov"},{"issue":"12","key":"6109_CR53","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1182\/blood.2021011895","volume":"139","author":"T Siddiqi","year":"2022","unstructured":"Siddiqi T, Soumerai JD, Dorritie KA et al (2022) Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed\/refractory CLL or SLL. Blood 139(12):1794\u20131806. https:\/\/doi.org\/10.1182\/blood.2021011895","journal-title":"Blood"},{"key":"6109_CR54","doi-asserted-by":"publisher","first-page":"101036","DOI":"10.1016\/j.blre.2022.101036","volume":"59","author":"P Dhakal","year":"2023","unstructured":"Dhakal P, Bates M, Tomasson MH, Sutamtewagul G, Dupuy A, Bhatt VR (2023) Acute myeloid leukemia resistant to venetoclax-based therapy: what does the future hold? Blood Rev 59:101036. https:\/\/doi.org\/10.1016\/j.blre.2022.101036","journal-title":"Blood Rev"},{"issue":"1","key":"6109_CR55","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1002\/ajh.26760","volume":"98","author":"AC Hristov","year":"2023","unstructured":"Hristov AC, Tejasvi T, Wilcox RA (2023) Cutaneous T-cell lymphomas: 2023 update on diagnosis, risk-stratification, and management. Am J Hematol 98(1):193\u2013209. https:\/\/doi.org\/10.1002\/ajh.26760","journal-title":"Am J Hematol"},{"key":"6109_CR56","doi-asserted-by":"publisher","first-page":"1150715","DOI":"10.3389\/fonc.2023.1150715","volume":"13","author":"J Zain","year":"2023","unstructured":"Zain J, Kallam A (2023) Challenges in nodal peripheral T-cell lymphomas: from biological advances to clinical applicability. Front Oncol 13:1150715. https:\/\/doi.org\/10.3389\/fonc.2023.1150715","journal-title":"Front Oncol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-06109-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-024-06109-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-06109-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T01:15:27Z","timestamp":1735866927000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-024-06109-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,28]]},"references-count":56,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["6109"],"URL":"https:\/\/doi.org\/10.1007\/s00277-024-06109-9","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,28]]},"assertion":[{"value":"25 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Medical Ethics Committee of Shandong Provincial Hospital (SWYX: NO.2023\u2009\u2212\u2009388), and \u201cthe consent to participate\u201d has been granted an exemption, because it was a retrospective and non-interventional study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}